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Inflammation and Cancer: New Targets for Therapy in Cancer 
 
Lisa M. Coussens. Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon 
Health & Sciences University, 2720 SW Moody Ave, KR-CDCB, Portland OR 97201. Email: 
coussenl@ohsu.edu 
 
The concept that leukocytes are critical components of solid tumors is now generally accepted, however, 
their role(s) in regulating aspects of neoplastic progression, and/or response to cytotoxic, targeted and/or 
immune therapy is only beginning to be understood.  Utilizing de novo mouse models of organ-specific solid 
tumor development (mammary, cutaneous, and pancreas carcinomas and mesothelioma), we now 
appreciate that adaptive leukocytes differentially regulate myeloid cell recruitment, activation and effector 
function, and in turn, activated tumor-infiltrating myeloid cells engage tissue-based programs to foster 
malignancy, and repress anti-tumor immunity by a diversity of mechanisms.  Treatment of tumor-bearing 
mice with therapeutic agents that disrupt lymphocyte-myeloid cell interaction, myeloid cell activation, or 
myeloid cell functionality generally slow primary tumor growth kinetics when combined with cytotoxic 
therapy; however, their impact on metastases is variable.  Similar to organ-specific regulatory programs co-
opted to foster primary tumor growth, regulation of metastatic seeding and outgrowth is also regulated by 
tissue- and organ-specific mechanisms. Based on this, it stands to reason that therapeutic strategies may 
not be efficacious in both primary and metastatic locations. To be presented will be our recent insights into 
organ and tissue-specific regulation of primary and metastatic cancer development by adaptive and innate 
immune cells, how systemic regulation of humoral immunity and complement-mediated pathways regulate 
pro- versus anti-tumor immune responses, and new studies evaluating how attenuating protumor properties 
of select lymphoid and myeloid cells can be exploited to enhance therapeutic responses to cytotoxic and 
immune-based therapy. 
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